Rothenstein, Jeffrey External Entity

Publications

Sort by

Selected publications

  • Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).  Journal of clinical oncology : official journal of the American Society of Clinical Oncology2017 Academic Article GET IT
    Times cited: 1

Other